Literature DB >> 12096230

The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century.

D Symmons1, G Turner, R Webb, P Asten, E Barrett, M Lunt, D Scott, A Silman.   

Abstract

BACKGROUND: It is 40 yr since the last age- and sex-specific estimates of the prevalence of rheumatoid arthritis (RA) for the UK were published. Since then the classification criteria for RA have been revised and there has been evidence of a fall in the incidence of RA, especially in women.
OBJECTIVES: To estimate the age- and sex-specific point prevalence of RA (defined as fulfilment of a modification of the 1987 ACR classification criteria for RA on the day of assessment). The estimate was made in the primary care setting in Norfolk, UK.
METHODS: A stratified random sample was drawn from seven age and gender bands. The 7050 individuals selected were mailed a screening questionnaire. Positive responders were invited to attend for a clinical examination. The sample was matched against the names in the Norfolk Arthritis Register (NOAR), a register of incident cases of inflammatory polyarthritis which has been in existence since 1990.
RESULTS: The overall response rate was 82%. Sixty-six cases of RA were identified. Extrapolated to the population of the UK, the overall minimum prevalence of RA is 1.16% in women and 0.44% in men. A number of incident cases of RA previously notified to NOAR were not identified as cases in the survey because they had entered into treatment-induced remission. In addition, some cases who failed to attend for examination had significant disability. These prevalence figures are therefore an underestimate.
CONCLUSIONS: The prevalence of RA in women, but not in men, in the UK may have fallen since the 1950s.

Entities:  

Mesh:

Year:  2002        PMID: 12096230     DOI: 10.1093/rheumatology/41.7.793

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  176 in total

1.  [Novel approach for the early detection of inflammatory rheumatic diseases in the population using a mobile screening unit].

Authors:  J Heinert; C Iking-Konert; M Blumenroth; O Sander; J Richter; M Schneider
Journal:  Z Rheumatol       Date:  2010-10       Impact factor: 1.372

2.  [Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis (ORA study)].

Authors:  I Heberlein; W Demary; H Bloching; J Braun; F Buttgereit; R Dreher; C Kuhn; U Lange; W Pollähne; A Zink; H Zeidler; H Häntzschel; H Raspe
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

3.  The burden of disease in rheumatoid arthritis.

Authors:  Till Uhlig; Rikke H Moe; Tore K Kvien
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

Review 4.  Early environmental factors and rheumatoid arthritis.

Authors:  C J Edwards; C Cooper
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

5.  Wear testing of a DJOA finger prosthesis in vitro.

Authors:  Thomas J Joyce
Journal:  J Mater Sci Mater Med       Date:  2010-02-11       Impact factor: 3.896

Review 6.  Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Lesley Uttley; Iñigo Bermejo; Shijie Ren; Marrissa Martyn-St James; Ruth Wong; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

7.  Prevalence and incidence of rheumatoid arthritis in South Korea.

Authors:  Yoon-Kyoung Sung; Soo-Kyung Cho; Chan-Bum Choi; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2012-12-20       Impact factor: 2.631

8.  Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

Authors:  Andrew Moore; Ceri Phillips; Elke Hunsche; James Pellissier; Simone Crespi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Immune-mediated disorders among women carriers of fragile X premutation alleles.

Authors:  Tri Indah Winarni; Weerasak Chonchaiya; Tanjung Ayu Sumekar; Paul Ashwood; Guadalupe Mendoza Morales; Flora Tassone; Danh V Nguyen; Sultana M H Faradz; Judy Van de Water; Kylee Cook; Alyssa Hamlin; Yi Mu; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2012-08-17       Impact factor: 2.802

Review 10.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.